Ethosuximide
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Ethosuximide. Ethosuximide is a 2-ethyl-2-methylsuccinimide. It impairs thalamic voltage gated calcium channels. Fully referenced neurology checklist.
Mode of action
- Ethosuximide is a 2-ethyl-2-methylsuccinimide
- It impairs thalamic voltage gated calcium channels
- It also acts on slow inactivated sodium and calcium-activated potassium currents
Indications
Locked: subscribe to see this section.
Dosing
Locked: subscribe to see this section.
Neurological side effects
Locked: subscribe to see this section.
Gastrointestinal side effects
Locked: subscribe to see this section.
Dermatological side effects
Locked: subscribe to see this section.
Haematological side effects
Locked: subscribe to see this section.
References
- Gören MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev 2007; 13:224-239.
- Capovilla G, Beccaria F, Veggiotti P, Rubboli G, Meletti S, Tassinari CA. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol 1999; 14:395-400.
- Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T 2010; 35:392-415.
- Massey GV, Dunn NL, Heckel JL, Myer EC, Russell EC. Aplastic anemia following therapy for absence seizures with ethosuximide. Pediatr Neurol 1994; 11:59-61.
- Masruha MR, Marques CM, Vilanova LC, de Seixas Alves MT, Peres MF, Rodrigues MG. Drug induced pseudolymphoma secondary to ethosuximide. JNNP 2005; 76:1610.
